Microfluidic, nanoliter-scale immunoassays for rapid SARS-CoV-2 antibody analysis in serology testing, and vaccine and biotherapeutics development
The unprecedented vaccine and therapeutic development efforts in response to the COVID-19 pandemic has created an urgent need for rapid, accurate, and sensitive assays to measure antibody responses to the SARS-CoV-2 virus. To meet this need, a microfluidic, nanoliter-scale immunoassay for the qualitative detection of total antibodies generated against the spike protein (RBD) of SARS-CoV-2 in human serum samples has been developed using the Gyrolab immunoassay platform. The assay shows specificity towards SARS-CoV-2 antibodies in serum samples, and a broad range of approximately 40 to 200,000 ng/mL. With an assay completion time of one hour for 112 data points, high-throughput analysis is possible for serology tests and for immunoassays during vaccine or antibody therapeutic development.